Monday, March 4, 2024
HomeSportEisai Presents Post-hoc Analysis Results of Eribulin Mesylate (HALAVEN) at the 2022...

Eisai Presents Post-hoc Analysis Results of Eribulin Mesylate (HALAVEN) at the 2022 European Society for Medical Oncology (ESMO) Congress

Eisai presents results of post hoc analysis of Eribulin mesylate (HALAVEN) at the 2022 European Society for Medical Oncology (ESMO) Congress Evaluating the efficacy of eribulin in metastatic HER2-low breast cancer by analysis of three clinical studies
Tokyo, September 12, 2022- (JCN Newswire) – Eisai Co ., Ltd. today announced the results of a post hoc analysis of three randomized, pivotal, Phase 3 studies (EMBRACE Trial/Study 305, Study 301 and Study 304) evaluating eribulin mesylate (marketed as HALAVEN). ) in combination with other chemotherapy (Physician’s Choice […] TPC], capecitabine and vinorelbine) in patients with metastatic breast cancer (mBC) with low or no HER2 expression, respectively. These data were presented as a poster at the European Society of Medical Oncology (ESMO) Annual Meeting (#ESMO22), September 9-13, 2022 in Paris, France (presentation: #259P). The HER2-low breast cancer subtype is a newly defined subtype consisting of tumors previously thought to be HER2-negative based on immunohistochemical (IHC) assays and in situ hybridization (ISH) assays. HER2-low tumors express small amounts of HER2 protein, but not enough to be considered HER2 positive. HER2-low was defined as 1+ or 2 by IHC and negative by ISH. Of the approximately 288,000 new cases of breast cancer in women expected to be diagnosed in the United States in 2022,(1) it is estimated that approximately 80-85% of patients were previously thought to have a HER2-negative subtype. Of these patients, approximately 60% are now considered to have the HER2-low subtype. (2) “In this post hoc analysis, the results seen in mBC patients whose tumors were thought to be HER2-low were consistent with the results of three pivotal Phase 3 trials,” Chief Scientific Officer , said Dr. Takashi Owa, Senior Vice President, Eisai Co., Ltd. “As the oncology community’s understanding of mBC continues to evolve, it is imperative that we continue to evaluate the role of existing therapies in new settings, thereby creating new opportunities for healthcare professionals. body of knowledge.”(1) National Institutes of Health, National Cancer Institute website, “Cancer Statistical Facts: Breast Cancer in Women”: https://seer.cancer.gov/statfacts/ html/breast.html
(2) U.S. Food and Drug Administration website, “FDA approves first drug for HER2-Low breast cancer Targeted Therapy”: bit.ly/3xc0N7q For more information, visit www.eisai.com/news/2022/pdf/enews202266pdf.pdf. Media inquiries:
PR
Eisai Co., Ltd.
+81-(0)3-3817-5120
Copyright © 2022 JCN Newswire. all rights reserved. A division of the Nippon Enterprise News Network.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

LAST NEWS

Featured NEWS